Mark Emalfarb
Vermögen: 4 Mio $ am 31.05.2026
Vermögen: 4 Mio $ am 31.05.2026
Mark A. Emalfarb is the founder of Dyadic International, Inc., founded in 1979, holding the title of Chief Executive Officer & Director.
Current jobs include Chairman & Chief Executive Officer at Dyadic International (USA), Inc., and Director at Biotechnology Development for Industry in Pharmaceuticals SLU since 2017.
Education includes an undergraduate degree from the University of Iowa, conferred in 1977.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.04.2026 | 4’832’667 ( 13.26% ) | 4 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| DYADIC INTERNATIONAL, INC. | Gründer | 01.01.1979 |
Dyadic International (USA), Inc.
Dyadic International (USA), Inc. BiotechnologyHealth Technology Researches and manufactures genes | Vorstandsvorsitzender | 05.10.2011 |
Biotechnology Development for Industry in Pharmaceuticals SLU
Biotechnology Development for Industry in Pharmaceuticals SLU Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company which produces recombinant proteins | Direktor/Vorstandsmitglied | 13.09.2017 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Dyadic International, Inc.
Dyadic International, Inc. Medical/Nursing ServicesHealth Services Manufactures genes and other biological products | Health Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dyadic International (USA), Inc.
Dyadic International (USA), Inc. BiotechnologyHealth Technology Researches and manufactures genes | Health Technology |
Biotechnology Development for Industry in Pharmaceuticals SLU
Biotechnology Development for Industry in Pharmaceuticals SLU Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company which produces recombinant proteins | Commercial Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen